Sarepta Therapeutics, Inc.
看多
已更新

SRPT Long

411
Sarepta Therapeutics
Focused on the development of precision genetic medicines to treat rare neuromuscular
and central nervous system diseases
investorrelations.sarepta.com/?_ga=2.49566691.415372990.1745780982-1018978192.1745780982

Major leader in treatment
- Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs)
- Explore perespective produts in Gene therapy and editing

Fundamentals:
- Growing Revenue and EPS
- Trading at historical low PE
- Far below market consensus $148

Technicals
- Near low 200VWAP extension 30% discount
交易結束:達到停損點

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。